Zura Bio Stock Price, News & Analysis (NASDAQ:ZURA) $3.99 -0.03 (-0.75%) (As of 11:37 AM ET) Add Compare Share Share Today's Range$3.92▼$4.0750-Day Range$4.00▼$7.0052-Week Range$3.91▼$37.55Volume46,423 shsAverage Volume315,813 shsMarket Capitalization$171.93 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Zura Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside316.0% Upside$16.60 Price TargetShort InterestHealthy0.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.74) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector298th out of 958 stocksBiological Products, Except Diagnostic Industry44th out of 146 stocks 3.6 Analyst's Opinion Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.60, Zura Bio has a forecasted upside of 316.0% from its current price of $3.99.Amount of Analyst CoverageZura Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.83% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 62.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZURA. Previous Next 2.4 News and Social Media Coverage News SentimentZura Bio has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zura Bio this week, compared to 2 articles on an average week.Search Interest3 people have searched for ZURA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have not sold or bought any company stock.Percentage Held by Insiders15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zura Bio are expected to grow in the coming year, from ($2.74) to ($0.98) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Zura Bio Stock (NASDAQ:ZURA)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.Read More ZURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZURA Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comZura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in BangkokNovember 30, 2023 | americanbankingnews.comShort Interest in Zura Bio Limited (NASDAQ:ZURA) Decreases By 62.9%December 7, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 14, 2023 | finance.yahoo.comZura Bio Appoints Arnout Ploos van Amstel to its Board of DirectorsNovember 13, 2023 | msn.comZura Bio GAAP EPS of -$0.18November 13, 2023 | finance.yahoo.comZura Bio Reports Third Quarter 2023 Financial Results and Recent Business HighlightsOctober 11, 2023 | msn.comLadenburg Thalmann Initiates Coverage of Zura Bio Ltd - (ZURA) with Buy RecommendationSeptember 12, 2023 | finance.yahoo.comZura Bio Enters into Sponsored Research Agreement with Benaroya Research InstituteDecember 7, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.September 7, 2023 | barrons.comZura Bio Ltd. WtSeptember 7, 2023 | finance.yahoo.comWe're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash WiselyAugust 25, 2023 | msn.comOppenheimer starts Zura Bio at outperform, cites potential of ZB-106August 25, 2023 | msn.comOppenheimer Initiates Coverage of Zura Bio Ltd - (ZURA) with Outperform RecommendationAugust 15, 2023 | msn.comRaymond James Maintains Zura Bio Ltd - (ZURA) Strong Buy RecommendationAugust 15, 2023 | markets.businessinsider.comWhere Zura Bio Stands With AnalystsAugust 14, 2023 | finance.yahoo.comZura Bio Reports Second Quarter 2023 Financial Results and Recent Business HighlightsJuly 20, 2023 | seekingalpha.comZURAW Zura Bio Limited WT EXP 032028June 23, 2023 | benzinga.comZura Bio shares are trading lower Wednesday amid possible profit-taking after the stock rallied on Tuesday.June 23, 2023 | seekingalpha.comZura Bio to join Russell 2000 and Russell 3000 indexesJune 23, 2023 | benzinga.comZura Bio shares are trading higher after the company announced it will join the Russell 2000 and Russell 3000 indexes.June 22, 2023 | seekingalpha.comZura Bio a new buy at Guggenheim on immunology, inflammation assetsJune 22, 2023 | investing.comZura Bio Ltd (94E)June 21, 2023 | fool.comZura Bio (NASDAQ: ZURA)June 21, 2023 | markets.businessinsider.comWhat's Going On With Zura Bio Stock TodayJune 20, 2023 | fool.comWhy Shares of Zura Bio Climbed TuesdayJune 14, 2023 | benzinga.comChardan Capital Initiates Coverage On Zura Bio with Buy Rating, Announces Price Target of $14June 6, 2023 | investorplace.comWhy Is Zura Bio (ZURA) Stock Up 9% Today?See More Headlines Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$22.00 Low Stock Price Target$10.00 Potential Upside/Downside+312.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.71% Return on Assets-38.33% Debt Debt-to-Equity RatioN/A Current Ratio6.15 Quick Ratio6.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.86 per share Price / Cash Flow4.65 Book Value($2.21) per share Price / Book-1.82Miscellaneous Outstanding Shares43,090,000Free Float36,285,000Market Cap$173.22 million OptionableNot Optionable Beta0.54 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David BradyHead of Business DevelopmentDr. Someit Sidhu M.D. (Age 34)CEO & Director Mr. Verender S. Badial (Age 51)Chief Financial Officer Dr. Gary Whale (Age 49)Chief Technology Officer Dr. Michael D. Howell Ph.D. (Age 46)Chief Scientific Officer & Head of Translational Science Ms. Kimberly Ann Davis (Age 55)Chief Legal Officer & Secretary Ms. Theresa Lowry (Age 49)Chief Human Resources Officer Dr. Christopher H. Cabell FACC (Age 54)M.D., MHS, Chief Medical Officer, Executive VP and Head of R&D More ExecutivesKey CompetitorsScilexNASDAQ:SCLXInvivydNASDAQ:IVVDHarpoon TherapeuticsNASDAQ:HARPMesoblastNASDAQ:MESOSemper Paratus AcquisitionNASDAQ:LGSTView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 630,000 shares on 11/15/2023Ownership: 3.667%Lynx1 Capital Management LPBought 9,917 shares on 11/14/2023Ownership: 0.023%Invesco Ltd.Bought 59,049 shares on 11/13/2023Ownership: 0.274%Eisler Capital US LLCBought 100,000 shares on 11/13/2023Ownership: 0.232%Northern Trust CorpBought 26,319 shares on 11/13/2023Ownership: 0.223%View All Insider TransactionsView All Institutional Transactions ZURA Stock Analysis - Frequently Asked Questions Should I buy or sell Zura Bio stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZURA shares. View ZURA analyst ratings or view top-rated stocks. What is Zura Bio's stock price target for 2024? 5 analysts have issued 12-month price objectives for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $22.00. On average, they anticipate the company's share price to reach $16.60 in the next year. This suggests a possible upside of 316.0% from the stock's current price. View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts. How have ZURA shares performed in 2023? Zura Bio's stock was trading at $29.42 at the start of the year. Since then, ZURA stock has decreased by 86.4% and is now trading at $3.99. View the best growth stocks for 2023 here. Are investors shorting Zura Bio? Zura Bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 171,200 shares, a decrease of 62.9% from the October 31st total of 461,900 shares. Based on an average trading volume of 129,700 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the company's stock are short sold. View Zura Bio's Short Interest. When is Zura Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our ZURA earnings forecast. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07. Who are Zura Bio's major shareholders? Zura Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (3.67%), Silverarc Capital Management LLC (0.94%), Invesco Ltd. (0.27%), Eisler Capital US LLC (0.23%), Northern Trust Corp (0.22%) and Charles Schwab Investment Management Inc. (0.22%). View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ZURA) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.